Table 1.

Characteristics cases and controls per cohort

	UCP			Rotterdam Study I			Rotterdam Study II			Rotterdam Study III
	Control	Case	p value	Control	Case	p value	Control	Case	p value	Control	Case	p value
Number	2617	158		4117	1575		2021	129		2421	505
Sex, % male	71	53	<0.001	47	27	<0.001	46	31	<0.001	42	54	<0.001
Age mean, years (SD)	58 (10.7)	60 (11.1)	0.009	68 (8.8)	70 (8.6)	<0.001	65 (7.8)	68 (9.1)	<0.001	57 (6.6)	58 (7.4)	0.007
Medication use, %
Beta-blockers	79	58	<0.001	15	13	0.080	15	16	0.519	14	17	0.096
Other antihypertensives	77	65	0.001	14	12	0.042	1	2	0.055	0	1	0.053
Corticosteroids	8	10	0.443	2	2	1.000	1	2	0.078	1	1	0.980
Bone-modifying drugs	8	6	0.754	0	0	NA	1	2	0.262	1	3	<0.001
Antidiabetic drugs	31	18	<0.001	4	5	0.093	5	8	0.025	4	6	0.354
Antidepressant drugs	6	7	0.604	2	2	0.535	5	6	0.530	7	6	0.449
Antipsychotic drugs	1	1	1.0	14	18	<0.001	10	12	0.152	10	6	0.006
Antiepileptic drugs	4	4	0.503	0	1	1.000	14	17	0.840	14	26	0.074
Sleep medication	15	22	0.017	14	15	0.604	13	20	0.006	9	6	0.038
NSAIDs	10	16	0.030	25	26	0.365	11	10	0.707	14	10	0.018
Immunosuppressive drugs	1	3	0.125	0	0	1.000	0	0	NA	1	1	0.925

Characteristics of the cases and controls of the UCP and Rotterdam Study cohorts

NA not applicable